S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$65.58
-1.12 (-1.68 %)
(As of 01/27/2021 09:02 AM ET)
Add
Compare
Today's Range
$65.57
Now: $65.58
$65.82
50-Day Range
$56.65
MA: $61.06
$68.16
52-Week Range
$56.56
Now: $65.58
$85.97
Volume811 shs
Average Volume10.15 million shs
Market Capitalization$82.21 billion
P/E Ratio67.61
Dividend Yield3.99%
Beta0.51
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences logo

MarketRank

Overall MarketRank

2.75 out of 5 stars

Medical Sector

4th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

1st out of 177 stocks

Analyst Opinion: 4.2Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Employees11,800
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.78 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Outstanding Shares1,253,528,000
Market Cap$82.21 billion
Next Earnings Date2/4/2021 (Confirmed)
OptionableOptionable
$65.58
-1.12 (-1.68 %)
(As of 01/27/2021 09:02 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock price been impacted by Coronavirus (COVID-19)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GILD shares have decreased by 9.5% and is now trading at $66.70.
View which stocks have been most impacted by COVID-19
.

Is Gilead Sciences a buy right now?

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 2 sell ratings, 14 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Gilead Sciences?

Wall Street analysts have given Gilead Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Gilead Sciences
.

How can I listen to Gilead Sciences' earnings call?

Gilead Sciences will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.90 by $0.21. The biopharmaceutical company earned $6.58 billion during the quarter, compared to analysts' expectations of $6.20 billion. Gilead Sciences had a net margin of 5.48% and a trailing twelve-month return on equity of 37.77%.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Wednesday, October 28th. Investors of record on Tuesday, December 15th will be given a dividend of $0.68 per share on Wednesday, December 30th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.08%. The ex-dividend date of this dividend is Monday, December 14th.
View Gilead Sciences' dividend history
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.72 per share and currently has a dividend yield of 3.99%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Gilead Sciences is 44.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.80% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY20 earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of $6.98-7.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.60. The company issued revenue guidance of $24.3-24.35 billion, compared to the consensus revenue estimate of $22.54 billion.

What price target have analysts set for GILD?

28 equities research analysts have issued 12 month price targets for Gilead Sciences' shares. Their forecasts range from $61.00 to $625.00. On average, they expect Gilead Sciences' stock price to reach $94.38 in the next twelve months. This suggests a possible upside of 41.5% from the stock's current price.
View analysts' price targets for Gilead Sciences
or view Wall Street analyst' top-rated stocks.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decline in short interest in December. As of December 31st, there was short interest totaling 17,670,000 shares, a decline of 14.8% from the December 15th total of 20,730,000 shares. Based on an average trading volume of 9,390,000 shares, the short-interest ratio is currently 1.9 days. Currently, 1.4% of the company's shares are short sold.
View Gilead Sciences' Short Interest
.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Mr. Daniel P. O'Day, Chairman & CEO (Age 57, Pay $10.86M)
  • Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 51, Pay $6.91M)
  • Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53, Pay $2.14M)
  • Ms. Johanna Mercier, Chief Commercial Officer (Age 51, Pay $2.55M)
  • Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 58, Pay $1.12M)
  • Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 59)
  • Ms. Jyoti K. Mehra, Exec. VP of HR
  • Dr. William A. Lee, Exec. VP of Research (Age 66)
  • Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 67)
  • Dr. Diana Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 50)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.18%), New York State Teachers Retirement System (0.13%), DNB Asset Management AS (0.12%), KAMES CAPITAL plc (0.10%), Confluence Investment Management LLC (0.09%) and Strs Ohio (0.05%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Bartlett & Co. LLC, State of Alaska Department of Revenue, RNC Capital Management LLC, Confluence Investment Management LLC, New York State Teachers Retirement System, Pinnacle Associates Ltd., and Thomasville National Bank. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, and Olsen Per Wold.
View insider buying and selling activity for Gilead Sciences
or view top insider-selling stocks.

Which major investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Candriam Luxembourg S.C.A., Sicart Associates LLC, Rhenman & Partners Asset Management AB, Louisiana State Employees Retirement System, Exchange Traded Concepts LLC, Nia Impact Advisors LLC, and Artemis Investment Management LLP.
View insider buying and selling activity for Gilead Sciences
or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $66.70.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $83.61 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.